Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

CanGoNano A training network on glyconanomaterials as precision tools to unveil key insights on the triggering of the antigen presenting cells against cancer

Coordinator
Universita Degli Studi Di Firenze, Italy
Runs
1 March 2026 to 28 February 2030
Status
Running
EU funding
€4.0m
Total cost
—
Partners
22 organisations in 10 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101226412

What the project is doing

In the project's own words, from its summary on CORDIS.

Immunotherapy is at the frontier of cancer treatment, with vaccine prototypes in phase III clinical trials. However, guidelines for the selection of the optimal antigen format (mRNA vs peptide) to be used in vaccine formulations are still not available. The glycoscience-oriented CanGoNano DN has identified this gap and proposes for the first time a research & training & innovation action that aims to unveil the molecular mechanisms of immune system activation at the molecular level.

Our innovative DN puts antigen presenting cells (APC) as the immune system hub to move forward on the rational selection of antigen formats towards next generation of cancer vaccines. Glyconanomaterials are precision tools for the controlled delivery of antigens to APC and will shed light on molecular mechanisms that rule APC activation according to antigen format. CanGoNano credibility and high quality are ensured by a partnership of experts in glycoscience & nanotechnology & immunology. 12 Academics, 6 SMEs & 1 clinical Institution encompass complementary & intersectoral expertise, and unique tools to train 14 doctoral candidates (DC).

The combination of interdisciplinary & excellent science, industry know-how and clinical perspective will cover the entire process from fundamental insights to innovative solutions. CanGoNano will create a critical mass of uniquely skilled researchers in glyconanotechnology. We will train DC on the synergic potential of glycoscience & nanotech to provide the missing knowledge in cancer immunotherapy, and will equip DC with transferrable skills to be in an advantageous position for job opportunities in academia and industry.

Deciphering the key interactions in APC activation expands the frontiers of knowledge and enables addressing key challenges in cancer immunotherapy. CanGoNano will strengthen the EU innovation capacity bringing new fundamental knowledge for the future development of precision anticancer vaccines to market and policy stakeholders.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di FirenzeFlorenceItalyCoordinator
Engenes Biotech GmbHWienAustriaParticipant
Universitaet Fuer Bodenkultur WienWienAustriaAssociatedpartner
Vaxine Pty LtdWarradaleAustraliaAssociatedpartner
Tuscan Organisation of Universitiesand Research 4 EuropeBruxelles / BrusselBelgiumAssociatedpartner
Asociacion Centro De Investigacion Cooperativa En Biomateriales- Cic BiomaguneSan SebastianSpainParticipant
Universidad Autonoma De MadridMadridSpainAssociatedpartner
Universidad Del Pais Vasco/ Euskal Herriko UnibertsitateaLeioaSpainAssociatedpartner
Universidad Internacional De La Rioja SALogronoSpainParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Universite De StrasbourgStrasbourgFranceAssociatedpartner
Carbohyde Zartkoruen Mukodo ReszvenytarsasagBudapestHungaryParticipant
Eotvos Lorand TudomanyegyetemBudapestHungaryAssociatedpartner
Glycoselect LtdDublinIrelandAssociatedpartner
Aptuit (verona) SRLVeronaItalyParticipant
Istituto Europeo Di Oncologia SRLMilanoItalyAssociatedpartner
Universita Degli Studi Di MilanoMilanoItalyParticipant
RiboPro B.V.OssNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsAssociatedpartner
Stichting VuAmsterdamNetherlandsAssociatedpartner
Universidade Nova De LisboaLisboaPortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI